[Radioimmunotherapy of follicular lymphoma: a step towards cure?].
Advanced stage follicular lymphoma is incurable by conventional treatment. Important progress has been observed with the development of new therapies based on monoclonal antibodies and on the use of radioimmunotherapy (RIT) in the treatment of non-Hodgkin lymphomas (NHL). Rituximab in combination with chemotherapy in the upfront setting significantly improved treatment outcome as compared with chemotherapy alone. Different studies also indicate that RIT has an important role in the management of NHL and could be beneficial in combination with chemotherapy. These two new treatment options have clearly distinctive mechanisms of action, rituximab being an exclusively biological treatment and RIT adding targeted systemic radiation therapy. Both RIT and the unlabeled antibody treatments might be further improved by different strategies including repetition of RIT or combination of different antibodies. We present here our experience with RIT using 131I-tositumomab (Bexxar) and discuss different topics regarding RIT, like the use of different antibodies, the best choice of the radioisotope or the place of radio-imaging. From the therapeutic point of view, we argue that the debate should not be as to which one among antibody immunotherapy or RIT should be best added to chemotherapy, but that all three treatments might be optimally combined with the aim to get the highest chance of cure for advanced stage follicular lymphoma.
Ketterer
Nicolas
N
Multidisciplinary Oncology Center, University Hospital of Lausanne, CHUV, BH-06, 1011 Lausanne, Switzerland. Nicolas.Ketterer@chuv.hospvd.ch
Bischof Delaloye
Angelika
A
Helg
Claudine
C
Luthi
François
F
Buchegger
Franz
F
D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001855:Bone Marrow Diseases / Q000209:etiology; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D003131:Combined Modality Therapy; D006801:Humans; D008224:Lymphoma, Follicular / Q000188:drug therapy / Q000532:radiotherapy*; D051379:Mice; D016499:Radioimmunotherapy / Q000009:adverse effects; D011874:Radiometry; D019275:Radiopharmaceuticals / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D011879:Radiotherapy Dosage; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D019275:Radiopharmaceuticals